Apellis Pharmaceuticals (APLS) is facing a decline in its stock price today, primarily driven by negative sentiment surrounding recent insider selling activities. Notably, the company's Chief Medical Officer was involved in these sales, which has contributed to a cautious outlook among analysts. Piper Sandler has maintained a Hold rating with a price target of $32.00, slightly below the last close of $33.00